VivoSeq
Other

Neonatal Opioid Withdrawal Syndrome

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Neonatal Opioid Withdrawal Syndrome is an early-stage landscape with 2 programs across 2 companies. The most active players are Hikma Pharmaceuticals LLC, Chiesi Farmaceutici S.p.A.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

67/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hikma Pharmaceuticals LLC

2 programs

Phase 3Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Morphine

Hikma Pharmaceuticals LLC

Methadone

Hikma Pharmaceuticals LLC

Approved
No programs

Analysis

Trial Status

3

clinical trials

Withdrawn1 · 33%
Terminated1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)
Withdrawn·WWomen and Infants Hospital of Rhode Island·Phase 3·NCT04455802
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
Terminated·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 2·NCT04104646·7 enrolled
Pragmatic, Randomized, Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)
Active, not recruiting·AAdvancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program·Phase 3·NCT04214834·189 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)